

Lucie Peuvrel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4477552/publications.pdf>

Version: 2024-02-01

57
papers

1,064
citations

304743

22
h-index

454955

30
g-index

61
all docs

61
docs citations

61
times ranked

1875
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, biological and histological characteristics of bullous pemphigoid associated with anti- PD-1/PD-L1 therapy: A national retrospective study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e511-e514.	2.4	17
2	Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. Cancers, 2021, 13, 3547.	3.7	31
3	Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases. Journal of the American Academy of Dermatology, 2019, 80, 558-562.	1.2	13
4	First case of trastuzumab emtansine-associated hemorrhagic telangiectasias treated with propranolol. Dermatologic Therapy, 2019, 32, e12756.	1.7	1
5	Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. European Journal of Dermatology, 2019, 29, 315-321.	0.6	14
6	TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Supportive Care in Cancer, 2018, 26, 2871-2877.	2.2	2
7	Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e39-e40.	2.4	13
8	BRAF mutations might be more common than supposed in vulvar melanomas. Experimental Dermatology, 2018, 27, 210-213.	2.9	17
9	Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. Journal of Immunology Research, 2018, 2018, 1-10.	2.2	23
10	Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma. Acta Dermato-Venereologica, 2018, 98, 406-410.	1.3	31
11	Three new cases of bullous pemphigoid during anti- PD-1 antibody therapy. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e104-e106.	2.4	16
12	Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma. Acta Dermato-Venereologica, 2018, 98, 530-531.	1.3	2
13	Positive margins after surgical excision of locoregional cutaneous melanoma metastasis and their impact on patient outcome. European Journal of Dermatology, 2018, 28, 661-667.	0.6	3
14	Histopathological aspects of cutaneous erythematous papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. International Journal of Dermatology, 2017, 56, 527-533.	1.0	30
15	Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients. Acta Dermato-Venereologica, 2017, 97, 483-488.	1.3	7
16	5-fluorouracil chemowraps for the treatment of multiple actinic keratoses. European Journal of Dermatology, 2017, 27, 635-640.	0.6	6
17	Exceptional Association of Syringotropic Mycosis Fungoides with Chronic Lymphocytic Leukaemia. Acta Dermato-Venereologica, 2016, 96, 263-264.	1.3	1
18	Acneiform rash: an unusual presentation of epithelioid haemangioma. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 470-472.	2.4	0

#	ARTICLE	IF	CITATIONS
19	Clinical significance of <scp>BRAF</scp> mutation status in circulating tumor <scp>DNA</scp> of metastatic melanoma patients at baseline. <i>Experimental Dermatology</i> , 2016, 25, 783-788.	2.9	34
20	Profile of vemurafenib-induced severe skin toxicities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 250-257.	2.4	27
21	Dramatic response of an inoperable Merkel cell carcinoma with imatinib. <i>JAAD Case Reports</i> , 2016, 2, 16-18.	0.8	4
22	Autoimmune thyroiditis and isotretinoin: real association or coincidence?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 125-126.	2.4	5
23	Early-Onset Vemurafenib-Induced DRESS Syndrome. <i>Dermatology</i> , 2016, 232, 126-128.	2.1	25
24	Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. <i>Journal of Neuro-Oncology</i> , 2016, 126, 355-360.	2.9	19
25	Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management. <i>Supportive Care in Cancer</i> , 2016, 24, 1689-1695.	2.2	13
26	Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive. <i>European Journal of Dermatology</i> , 2015, 25, 452-456.	0.6	19
27	Vorinostat for Refractory or Relapsing Epidermotropic T-cell Lymphoma: A Retrospective Cohort Study of 15 Patients. <i>Acta Dermato-Venereologica</i> , 2015, 95, 72-77.	1.3	13
28	Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing) Tj ETQq0 0 0 rgBT /Overlock 10 T	4.25	26
29	Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1006-1009.	2.4	40
30	Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. <i>Oncology Reports</i> , 2014, 32, 808-814.	2.6	6
31	Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1468-1470.	0.7	37
32	Guidelines of the French Society of Otorhinolaryngology (SFORL), short version. Extension assessment and principles of resection in cutaneous head and neck tumors. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2014, 131, 375-383.	0.7	16
33	Predictive value of Tâ€cell clone and <scp>CD</scp>13 antigen in parapsoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 518-520.	2.4	2
34	Efficacy of cetuximab in the treatment of squamous cell carcinoma. <i>Journal of Dermatological Treatment</i> , 2014, 25, 424-427.	2.2	54
35	Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib. <i>Journal of Neuro-Oncology</i> , 2014, 120, 147-154.	2.9	42
36	Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2014, 37, 348-350.	2.4	36

#	ARTICLE	IF	CITATIONS
37	Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management. American Journal of Clinical Dermatology, 2014, 15, 425-444.	6.7	30
38	BRAF mutation in circulating DNA of melanoma patients at baseline and intertumor heterogeneity.. Journal of Clinical Oncology, 2014, 32, 9017-9017.	1.6	0
39	Detection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiency.. Journal of Clinical Oncology, 2014, 32, 9069-9069.	1.6	0
40	Incidence and characteristics of melanoma brain metastases appearing during vemurafenib treatment.. Journal of Clinical Oncology, 2014, 32, 9042-9042.	1.6	0
41	Survey on the management of skin toxicity associated with EGFR inhibitors amongst French Physicians. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 419-429.	2.4	18
42	Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Expert Opinion on Pharmacotherapy, 2013, 14, 1711-1721.	1.8	22
43	Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: A prospective open study and review of the literature. Journal of the American Academy of Dermatology, 2013, 69, 890-897.	1.2	43
44	Melanoma and Rituximab: An Incidental Association?. Dermatology, 2013, 226, 274-278.	2.1	23
45	Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. European Journal of Dermatology, 2013, 23, 879-881.	0.6	40
46	Atypical cutaneous vasculitis under lapatinib. European Journal of Dermatology, 2013, 23, 540-541.	0.6	3
47	Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review. Oncologist, 2012, 17, 555-568.	3.7	44
48	Onychopathy Induced by Temsirolimus, a Mammalian Target of Rapamycin Inhibitor. Dermatology, 2012, 224, 204-208.	2.1	26
49	Evaluation of Quality of Life after a Medical Corrective Make-Up Lesson in Patients with Various Dermatoses. Dermatology, 2012, 224, 374-380.	2.1	34
50	Tissue Biomarkers in Melanoma Patients Treated with TIL. PLoS ONE, 2012, 7, e48729.	2.5	4
51	Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Supportive Care in Cancer, 2012, 20, 909-921.	2.2	45
52	Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. Supportive Care in Cancer, 2012, 20, 1395-1404.	2.2	29
53	Systemic Rituximab in Multifocal Primary Cutaneous Follicle Centre Lymphoma. Acta Dermato-Venereologica, 2011, 91, 562-567.	1.3	12
54	Treatment of a multicentric Merkel cell carcinoma using imatinib. European Journal of Dermatology, 2011, 21, 1009-1010.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Is primary melanoma ulceration a factor of good response to adoptive immunotherapy?. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1311-1317.	2.4	0
56	Sudden Onset of an Aggressive Cutaneous Lymphoma in a Young Patient With Psoriasis: Role of Immunosuppressants. Acta Dermato-Venereologica, 2010, 90, 616-620.	1.3	18
57	Impact of a campaign to train general practitioners in screening for melanoma. European Journal of Cancer Prevention, 2009, 18, 225-229.	1.3	12